Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

featured

Published in Metastatic Breast Cancer and

Expert Opinion / Guidelines · April 27, 2016

New Drug Approvals for Oncology in 2015: Various Solid Tumors

: PracticeUpdate Editorial Team

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Additional Info

Disclosures

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

featured

2022 Top Story in Brain Cancer: Proton Craniospinal Irradiation for Leptomeningeal Disease

Commentary · December 08, 2022
featured

2022 Top Story in Brain Cancer: GD2-CAR T-Cell Therapy for H3K27M-Mutated Diffuse Midline Gliomas

Commentary · December 06, 2022
featured

2022 Top Story in Brain Cancer: Proton Craniospinal Irradiation vs Photon Involved-Field Radiotherapy for Solid Tumor Leptomeningeal Metastasis

Commentary · December 06, 2022
story of the week

Autologous Tumor Lysate–Loaded Dendritic Cell Vaccination Extends Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

JAMA Oncol · December 05, 2022

updated
story of the week

Efficacy and Safety of Trametinib With or Without Dabrafenib for Pediatric BRAF V600–Mutant Low-Grade Glioma

J. Clin. Oncol · December 05, 2022
featured

Primary Brain and Other CNS Tumors Diagnosed in the US From 2015 to 2019

Neuro-oncology · November 29, 2022
story of the week

Long-Term Outcomes Following Postoperative SRS vs WBRT for Resected Brain Metastasis

JAMA Oncol · November 22, 2022

updated
featured

Palliative and End-of-Life Care in Adults With Malignant Brain Tumors

Neuro-oncology · November 16, 2022
story of the week

Efficacy of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

J. Clin. Oncol · November 15, 2022

updated
story of the week

Concurrent Bevacizumab and Re-Irradiation vs Bevacizumab Alone for Treatment of Recurrent Glioblastoma

J. Clin. Oncol · November 14, 2022

Metastatic Breast Cancer

New Drug Approvals for Oncology in 2015: Various Solid Tumors

Additional Info

Brain Cancer Center of Excellence

2022 Top Story in Brain Cancer: Proton Craniospinal Irradiation for Leptomeningeal Disease

2022 Top Story in Brain Cancer: GD2-CAR T-Cell Therapy for H3K27M-Mutated Diffuse Midline Gliomas

2022 Top Story in Brain Cancer: Proton Craniospinal Irradiation vs Photon Involved-Field Radiotherapy for Solid Tumor Leptomeningeal Metastasis

Autologous Tumor Lysate–Loaded Dendritic Cell Vaccination Extends Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

Efficacy and Safety of Trametinib With or Without Dabrafenib for Pediatric BRAF V600–Mutant Low-Grade Glioma

Primary Brain and Other CNS Tumors Diagnosed in the US From 2015 to 2019

Long-Term Outcomes Following Postoperative SRS vs WBRT for Resected Brain Metastasis

Palliative and End-of-Life Care in Adults With Malignant Brain Tumors

Efficacy of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

Concurrent Bevacizumab and Re-Irradiation vs Bevacizumab Alone for Treatment of Recurrent Glioblastoma

Further Reading

Efficacy and Safety of Trastuzumab Deruxtecan Plus Nivolumab in Patients With HER2-Expressing Metastatic Breast or Urothelial Cancer

Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Treatment Failure in ER+ Metastatic Breast Cancer

Prophylactic Efficacy of Olanzapine-Based Therapy for Trastuzumab Deruxtecan–Associated Nausea and Vomiting in Patients With HER2-Positive or HER2-Low Breast Cancer

Outcomes and Prognostic Factors Associated With Brain Metastasis in Triple-Negative Breast Cancer

Outcomes of Datopotamab Deruxtecan vs Chemotherapy in Previously Treated Patients With Inoperable/Metastatic HR+/HER2− Breast Cancer

Pharmacokinetics and Pharmacogenomics of Ribociclib in Black Patients With Metastatic Breast Cancer

Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups

Acquired Gene Alterations in Patients Treated With Endocrine Therapy ± Ribociclib Using Baseline and End-of-Treatment ctDNA Samples

Safety of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, HR+/HER2− Advanced or Metastatic Breast Cancer

Outcomes of Pembrolizumab Plus Chemotherapy in Asian Patients With Advanced TNBC

Outcomes of Imlunestrant, an Oral SERD, as Monotherapy and in Combination With Targeted Therapy in ER+/HER2− Advanced Breast Cancer

Recently Updated